Intersect ENT Inc (NASDAQ:XENT) General Counsel David Aaron Lehman sold 36,000 shares of the company’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $32.75, for a total value of $1,179,000.00. Following the completion of the sale, the general counsel now owns 45,000 shares of the company’s stock, valued at $1,473,750. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Intersect ENT Inc (NASDAQ XENT) traded up $0.65 during midday trading on Wednesday, hitting $32.50. The company had a trading volume of 241,245 shares, compared to its average volume of 295,669. Intersect ENT Inc has a 1 year low of $10.95 and a 1 year high of $34.40.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The firm had revenue of $22.31 million during the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) EPS. analysts anticipate that Intersect ENT Inc will post -0.63 earnings per share for the current fiscal year.
Several equities research analysts have weighed in on XENT shares. Bank of America upped their target price on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Zacks Investment Research cut Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Canaccord Genuity upped their price objective on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. Northland Securities restated a “hold” rating and set a $25.00 price objective on shares of Intersect ENT in a research note on Friday, November 3rd. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Intersect ENT currently has a consensus rating of “Buy” and a consensus price target of $32.29.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Intersect ENT Inc (XENT) General Counsel Sells 36,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/13/insider-selling-intersect-ent-inc-xent-general-counsel-sells-36000-shares-of-stock.html.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.